Camlin Fine Sciences financials

·ChemicalsChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹520cr+22.7% on Q1 FY26
Net profit
−₹33.6cr−₹10.7 cr in Q1 FY26
EBITDA margin
1.8%−2.7 pts on Q1 FY26
EPS
−₹1.65−₹0.53 in Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue520424+22.7%
EBITDA9.319.0−51.3%
EBITDA margin1.8%4.5%−2.7 pts
Profit before tax−33.7−5.2—
Net profit−33.6−10.7—
EPS−₹1.65−₹0.53—

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹520 crNet profit₹−33.6 crNet margin−6.5%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
1,581————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
10910914280.393.7
−40.1−40.1−26.9−7.84.7
668668646658780
2,101————
1,8621,7231,6671,6131,682
—+3.4%+3.3%−4.1%—
85.910720873.9205
4.6%6.2%12.5%4.6%12.2%
10.436.0144−4.7143
0.623.5−158−10539.8
0.0%1.4%−9.5%−6.5%2.4%
₹0.31₹1.44−₹7.24−₹4.83₹2.71
—+119.9%−49.9%−278.0%—
—82.126.713950.9
—−57.6−42.4−60.6−144
24.524.5−15.778.4−93.4
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

CAMLINFINE₹82.32

Camlin Fine Sciences Limited

· Chemicals
₹ CrorePeersCLEANDEEPAKNTRBAYERCROPTIRUMALCHMATULSHKPAUSHAKLTDANURASMcap ₹1,581 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————1,581.3
- Cash, Equiv & ST Investments93.780.3142.1108.6108.6
+ Minority Interest4.7-7.8-26.9-40.1-40.1
+ Total Debt779.6657.7645.6668.1668.1
Enterprise Value————2,100.8
Revenue1,681.61,613.11,666.51,723.31,861.7
Growth %, YoY—-4.1+3.3+3.4—
EBITDA205.373.9208.1106.985.9
Margin %12.214.5812.496.204.61
EBIT142.8-4.7144.336.010.4
Net Income39.8-104.9-158.123.50.6
Margin %2.37-6.50-9.491.370.03
EPS, Adj (current shares)2.71-4.83-7.241.440.31
Growth %, YoY—-278.0-49.9+119.9—
Cash from Operations50.9139.026.782.1—
Capital Expenditures-144.3-60.6-42.4-57.6—
Free Cash Flow-93.478.4-15.724.524.5
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Camlin Fine Sciences financials and key ratios

Prices at the previous close · figures from the company's filings with NSE

Camlin Fine Sciences (NSE: CAMLINFINE) had a market capitalisation of ₹1,581 crore at the previous close (₹82.32 a share), a PE ratio of 268.8 on the last four quarters' profit and a price-to-book ratio of 1.52. In FY26 its consolidated net profit attributable to shareholders was ₹27.6 crore on revenue of ₹1,723 crore; in Q1 FY27 (April–June 2026) it was a loss of ₹31.7 crore. Its debt-to-equity ratio was 0.67 on 31 March 2026. Promoters held 48.03% of the shares on 30 September 2026.

Share price used
₹82.32 · previous close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Camlin Fine Sciences at a glance · consolidated

Market cap
₹1,581 Crat ₹82.32 · previous close
PE ratio (last 4 quarters)
268.857.2 on FY26 profit
Price to book (PB)
1.52book value ₹54.18 a share
ROE (FY26)
2.8%+18.6 pts vs FY25ROCE 2.9%
Debt to equity
0.67net debt ₹515 Cr
Promoter holding
48.03%unchanged vs 30 Jun 202630 September 2026
Net worth
₹1,041 Cr+15.4% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
₹24.5 Cr
EPS (FY26)
₹1.46

Questions

What is the Camlin Fine Sciences PE ratio today?

Camlin Fine Sciences' PE ratio is 268.8 at the previous close (₹82.32 a share): a market capitalisation of ₹1,581 crore divided by consolidated net profit attributable to shareholders of ₹5.9 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit attributable to shareholders (₹27.6 crore) it is 57.2. These four quarters include net exceptional items of −₹36.6 crore (one-off charges reported separately), so the ratio on recurring profit would differ.

What is the Camlin Fine Sciences PB ratio (price to book value)?

Camlin Fine Sciences' price-to-book (PB) ratio is 1.52 at the previous close: a market capitalisation of ₹1,581 crore divided by shareholders' equity (book value) of ₹1,041 crore on 31 March 2026. That is a book value of ₹54.18 per share against a share price of ₹82.32.

What is the Camlin Fine Sciences ROE and ROCE?

In FY26, Camlin Fine Sciences' return on equity (ROE) was 2.8% and its return on capital employed (ROCE) was 2.9%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was −15.7% and ROCE 12.0%.

What is the Camlin Fine Sciences market cap?

Camlin Fine Sciences' market capitalisation was ₹1,581 crore at the previous close: 19.21 crore shares at ₹82.32 each.

Is Camlin Fine Sciences debt free?

No. Camlin Fine Sciences had borrowings of ₹668 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.67. Its cash and current investments were ₹153 crore, so its net debt was ₹515 crore.

What is the Camlin Fine Sciences EPS?

Camlin Fine Sciences' basic earnings per share (EPS) were ₹1.46 in FY26. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹0.27.

What is the Camlin Fine Sciences debt to equity ratio?

Camlin Fine Sciences' debt-to-equity ratio was 0.67 on 31 March 2026: borrowings of ₹668 crore against total equity of ₹1,001 crore. A year earlier, on 31 March 2025, it was 0.74.

What is the Camlin Fine Sciences net worth?

Camlin Fine Sciences' net worth — shareholders' equity in its consolidated balance sheet — was ₹1,041 crore on 31 March 2026, up 15.4% from ₹902 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹1,581 crore at the previous close.

What is the Camlin Fine Sciences promoter holding?

Promoters held 48.03% of Camlin Fine Sciences on 30 September 2026, unchanged from the previous quarter and down 1.05 percentage points from 49.08% a year earlier, according to the shareholding pattern filed with NSE.

What is the Camlin Fine Sciences book value per share?

Camlin Fine Sciences' book value per share was ₹54.18 on 31 March 2026: shareholders' equity of ₹1,041 crore divided by the 19.21 crore shares in issue, up 12.9% from ₹47.98 a year earlier. The share price at the previous close was ₹82.32.

What is the Camlin Fine Sciences free cash flow?

In FY26, Camlin Fine Sciences generated ₹82.1 crore of cash from operations and spent ₹57.6 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹24.5 crore. In FY25 it was −₹15.7 crore.

What are the Camlin Fine Sciences latest quarterly results?

Camlin Fine Sciences' latest results are for Q1 FY27 (April–June 2026), filed on 11 August 2026: consolidated net loss ₹31.7 crore, wider than the loss of ₹10 crore in Q1 FY26; revenue from operations ₹520 crore, up 22.7% year on year.

What is the Camlin Fine Sciences shareholding pattern?

On 30 September 2026, Camlin Fine Sciences' shares were held by promoters 48.03%, foreign portfolio investors (FII/FPI) 0.95%, domestic institutions (DII) 5.32% (including mutual funds at 4.97%) and retail and other non-institutional investors 45.70%. Over the year, FII holding was down 1.17 percentage points from 2.12% and DII holding was down 0.16 percentage points from 5.48%.

What is the Camlin Fine Sciences revenue and profit in FY26?

In FY26 (April 2025–March 2026), Camlin Fine Sciences' consolidated net profit attributable to shareholders was ₹27.6 crore, against a loss of ₹139 crore in FY25, on revenue from operations of ₹1,723 crore (up 3.4%). Over three years, from FY23, net profit was down 47.0%.

Camlin Fine Sciences vs Clean Science and Technology: how do they compare?

In FY26, Camlin Fine Sciences earned net profit attributable to shareholders of ₹27.6 crore on revenue of ₹1,723 crore, against ₹230 crore on ₹957 crore for Clean Science and Technology. Camlin Fine Sciences' operating margin was 2.1% (Clean Science and Technology 29.0%) and its return on equity 2.8% (Clean Science and Technology 15.3%).

When are the Camlin Fine Sciences next results?

Camlin Fine Sciences will announce its Q2 FY27 results (July–September 2026) on Tuesday, 3 November 2026, the date of the board meeting it has notified to the exchanges.

How does Camlin Fine Sciences compare with its peers?

On FY26 consolidated figures, against Clean Science and Technology, Deepak Nitrite and Bayer Cropscience: Camlin Fine Sciences' operating margin of 2.1% is the lowest of the four (Clean Science and Technology 29.0%, Deepak Nitrite 9.6%, Bayer Cropscience 13.7%; peer average 17.4%); its return on equity of 2.8% is the lowest of the four (Clean Science and Technology 15.3%, Deepak Nitrite 9.8%, Bayer Cropscience 23.7%; peer average 16.3%).

Where do these Camlin Fine Sciences figures come from?

From Camlin Fine Sciences' own consolidated results, balance sheets and shareholding patterns filed with NSE. Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.